Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy

A Case Report

Paola Cianci, Silvia Salvatore, Alex Moretti, Angela Berardinelli, Alessandro Salvatoni, Maddalena Marinoni, Massimo Agosti

Research output: Contribution to journalArticle

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronically progressive or relapsing sensorimotor disorder presumably due to antibody-mediated reactions. It is a rare condition in children, with estimated prevalence as 0.48 per 100,000 among patients younger than 20 years of age. Recommended treatments include immune modulators, intravenous immunoglobulins (IVIgs), steroids, and plasmapheresis. Management of pediatric CIDP is challenging because of the lack of evidence-based efficacy of the current therapies in children. Because of the rarity of this condition, there are no double-blind randomized studies to support the therapeutic choice as well as to identify the optimal first-line therapeutic regimen. IVIgs are widely used but the intravenous administration is usually uncomfortable, especially for children. Subcutaneous immunoglobulins (SCIgs) have proven to be effective in adults with CIDP and in children affected by antibody deficiencies and other different immune and inflammatory disorders. Herein, we described the case of a 7-year-old boy, affected by CIDP who clinically responded to IVIg but was dependent on this therapy. In order to improve his quality of life, we switched to SCIg with excellent result.

Original languageEnglish
Pages (from-to)38-41
Number of pages4
JournalJournal of Pediatric Neurosciences
Volume14
Issue number1
DOIs
Publication statusPublished - Jul 19 2019

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Immunoglobulins
Intravenous Immunoglobulins
Therapeutics
Plasmapheresis
Antibodies
Immune System Diseases
Double-Blind Method
Intravenous Administration
Steroids
Quality of Life
Pediatrics

Cite this

Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy : A Case Report. / Cianci, Paola; Salvatore, Silvia; Moretti, Alex; Berardinelli, Angela; Salvatoni, Alessandro; Marinoni, Maddalena; Agosti, Massimo.

In: Journal of Pediatric Neurosciences, Vol. 14, No. 1, 19.07.2019, p. 38-41.

Research output: Contribution to journalArticle

Cianci, Paola ; Salvatore, Silvia ; Moretti, Alex ; Berardinelli, Angela ; Salvatoni, Alessandro ; Marinoni, Maddalena ; Agosti, Massimo. / Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy : A Case Report. In: Journal of Pediatric Neurosciences. 2019 ; Vol. 14, No. 1. pp. 38-41.
@article{f8d5247a96a04ef19e54bd40e69223ec,
title = "Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report",
abstract = "Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronically progressive or relapsing sensorimotor disorder presumably due to antibody-mediated reactions. It is a rare condition in children, with estimated prevalence as 0.48 per 100,000 among patients younger than 20 years of age. Recommended treatments include immune modulators, intravenous immunoglobulins (IVIgs), steroids, and plasmapheresis. Management of pediatric CIDP is challenging because of the lack of evidence-based efficacy of the current therapies in children. Because of the rarity of this condition, there are no double-blind randomized studies to support the therapeutic choice as well as to identify the optimal first-line therapeutic regimen. IVIgs are widely used but the intravenous administration is usually uncomfortable, especially for children. Subcutaneous immunoglobulins (SCIgs) have proven to be effective in adults with CIDP and in children affected by antibody deficiencies and other different immune and inflammatory disorders. Herein, we described the case of a 7-year-old boy, affected by CIDP who clinically responded to IVIg but was dependent on this therapy. In order to improve his quality of life, we switched to SCIg with excellent result.",
author = "Paola Cianci and Silvia Salvatore and Alex Moretti and Angela Berardinelli and Alessandro Salvatoni and Maddalena Marinoni and Massimo Agosti",
year = "2019",
month = "7",
day = "19",
doi = "10.4103/jpn.JPN_132_18",
language = "English",
volume = "14",
pages = "38--41",
journal = "Journal of Pediatric Neurosciences",
issn = "1817-1745",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

TY - JOUR

T1 - Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy

T2 - A Case Report

AU - Cianci, Paola

AU - Salvatore, Silvia

AU - Moretti, Alex

AU - Berardinelli, Angela

AU - Salvatoni, Alessandro

AU - Marinoni, Maddalena

AU - Agosti, Massimo

PY - 2019/7/19

Y1 - 2019/7/19

N2 - Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronically progressive or relapsing sensorimotor disorder presumably due to antibody-mediated reactions. It is a rare condition in children, with estimated prevalence as 0.48 per 100,000 among patients younger than 20 years of age. Recommended treatments include immune modulators, intravenous immunoglobulins (IVIgs), steroids, and plasmapheresis. Management of pediatric CIDP is challenging because of the lack of evidence-based efficacy of the current therapies in children. Because of the rarity of this condition, there are no double-blind randomized studies to support the therapeutic choice as well as to identify the optimal first-line therapeutic regimen. IVIgs are widely used but the intravenous administration is usually uncomfortable, especially for children. Subcutaneous immunoglobulins (SCIgs) have proven to be effective in adults with CIDP and in children affected by antibody deficiencies and other different immune and inflammatory disorders. Herein, we described the case of a 7-year-old boy, affected by CIDP who clinically responded to IVIg but was dependent on this therapy. In order to improve his quality of life, we switched to SCIg with excellent result.

AB - Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronically progressive or relapsing sensorimotor disorder presumably due to antibody-mediated reactions. It is a rare condition in children, with estimated prevalence as 0.48 per 100,000 among patients younger than 20 years of age. Recommended treatments include immune modulators, intravenous immunoglobulins (IVIgs), steroids, and plasmapheresis. Management of pediatric CIDP is challenging because of the lack of evidence-based efficacy of the current therapies in children. Because of the rarity of this condition, there are no double-blind randomized studies to support the therapeutic choice as well as to identify the optimal first-line therapeutic regimen. IVIgs are widely used but the intravenous administration is usually uncomfortable, especially for children. Subcutaneous immunoglobulins (SCIgs) have proven to be effective in adults with CIDP and in children affected by antibody deficiencies and other different immune and inflammatory disorders. Herein, we described the case of a 7-year-old boy, affected by CIDP who clinically responded to IVIg but was dependent on this therapy. In order to improve his quality of life, we switched to SCIg with excellent result.

U2 - 10.4103/jpn.JPN_132_18

DO - 10.4103/jpn.JPN_132_18

M3 - Article

VL - 14

SP - 38

EP - 41

JO - Journal of Pediatric Neurosciences

JF - Journal of Pediatric Neurosciences

SN - 1817-1745

IS - 1

ER -